Cardiff Oncology Valuation
| CRDF Stock | USD 2.61 0.07 2.76% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Cardiff Oncology shows a prevailing Real Value of $3.73 per share. The current price of the firm is $2.61. Our model approximates the value of Cardiff Oncology from analyzing the firm fundamentals such as Return On Equity of -0.68, shares outstanding of 51.13 M, and Operating Margin of (76.37) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cardiff Oncology's valuation include:
Price Book 2.702 | Enterprise Value 77.5 M | Enterprise Value Ebitda (3.66) | Price Sales 193.981 | Enterprise Value Revenue 112.6135 |
Undervalued
Today
Please note that Cardiff Oncology's price fluctuation is very risky at this time. Calculation of the real value of Cardiff Oncology is based on 3 months time horizon. Increasing Cardiff Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cardiff stock is determined by what a typical buyer is willing to pay for full or partial control of Cardiff Oncology. Since Cardiff Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cardiff Stock. However, Cardiff Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.61 | Real 3.73 | Target 7.33 | Hype 2.52 | Naive 2.59 |
The real value of Cardiff Stock, also known as its intrinsic value, is the underlying worth of Cardiff Oncology Company, which is reflected in its stock price. It is based on Cardiff Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cardiff Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cardiff Oncology helps investors to forecast how Cardiff stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cardiff Oncology more accurately as focusing exclusively on Cardiff Oncology's fundamentals will not take into account other important factors: When choosing an evaluation method for Cardiff Oncology, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Cardiff Oncology Cash |
|
Cardiff Valuation Trend
Comparing Cardiff Oncology's enterprise value against its market capitalization is a good way to estimate the value of Cardiff Oncology uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Cardiff Oncology Total Value Analysis
Cardiff Oncology is currently forecasted to have valuation of 77.48 M with market capitalization of 133.46 M, debt of 2.15 M, and cash on hands of 122.01 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Cardiff Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
77.48 M | 133.46 M | 2.15 M | 122.01 M |
Cardiff Oncology Investor Information
About 26.0% of the company shares are held by institutions such as insurance companies. The book value of Cardiff Oncology was currently reported as 1.01. The company recorded a loss per share of 0.95. Cardiff Oncology last dividend was issued on the 20th of February 2019. The entity had 1:6 split on the 20th of February 2019. Based on the key measurements obtained from Cardiff Oncology's financial statements, Cardiff Oncology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Cardiff Oncology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cardiff Oncology has an asset utilization ratio of 0.6 percent. This implies that the Company is making $0.005978 for each dollar of assets. An increasing asset utilization means that Cardiff Oncology is more efficient with each dollar of assets it utilizes for everyday operations.Cardiff Oncology Ownership Allocation
Cardiff Oncology holds a total of 51.13 Million outstanding shares. Cardiff Oncology shows 6.6 percent of its outstanding shares held by insiders and 25.97 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cardiff Oncology Profitability Analysis
The company reported the previous year's revenue of 488 K. Net Loss for the year was (41.44 M) with loss before overhead, payroll, taxes, and interest of (26.72 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cardiff Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cardiff Oncology and how it compares across the competition.
About Cardiff Oncology Valuation
The stock valuation mechanism determines Cardiff Oncology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Cardiff Oncology. We calculate exposure to Cardiff Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cardiff Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 488 K | 512.4 K | |
| Pretax Profit Margin | (84.92) | (89.17) | |
| Operating Profit Margin | (93.06) | (97.71) | |
| Net Loss | (84.92) | (89.17) | |
| Gross Profit Margin | 0.55 | 0.58 |
Cardiff Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Cardiff Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 44.7 M |
Cardiff Oncology Current Valuation Indicators
Valuation refers to the process of determining the present value of Cardiff Oncology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cardiff we look at many different elements of the entity such as Cardiff's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cardiff Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cardiff Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cardiff Oncology's worth.Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |